Inhibikase Therapeutics (IKT) Operating Income Growth (3y) (2023 - 2026)

Inhibikase Therapeutics (IKT) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -1,580.97%
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 32.96%
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn -29.67%
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -50.81%
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - 16.35%
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 13.47%
9 Abivax 91.71 Bn 91.71 Bn - -
10 Inhibikase Therapeutics 285.17 Mn 114.80 Mn - -55.83%

Historic Data

Download Data
DateValue
Mar 31, 2026 -55.83%
Dec 31, 2025 -47.02%
Sep 30, 2025 -41.43%
Jun 30, 2025 -32.66%
Mar 31, 2025 -46.52%
Dec 31, 2024 -36.88%
Sep 30, 2024 -9.23%
Jun 30, 2024 -24.32%
Mar 31, 2024 -22.13%
Dec 31, 2023 -54.21%
Sep 30, 2023 -92.97%
Jun 30, 2023 -146.54%
Mar 31, 2023 -105.92%